

Product datasheet

anti-Keratin K19 mouse monoclonal, Ks19.2 (Z105.6), liquid, purified

Short overview

Cat. No.	690029
Quantity	1 ml (50 µg/ml)
Concentration	50 µg/ml (50 µg)

Product description

Host	Mouse
Antibody Type	Monoclonal
Isotype	IgG2b
Formulation	PBS buffer, pH 7.4 with 0.09% sodium azide and 0.5 % BSA
UniprotID	P08728 (Bovine), P08727 (Human), Q63279 (Rat)
Synonym	Keratin, type I cytoskeletal 19, Cytokeratin-19, CK-19, Keratin-19, K19, KRT19
Conjugate	Unconjugated
Purification	Affinity chromatography
Storage	Short term at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles
Intended use	Research use only
Application	ELISA, ICC/IF, IHC, WB
Reactivity	Bovine, Human, Rabbit, Rat
No reactivity	Chicken, Mouse, Woodchuck, Xenopus

Applications

ELISA	Assay dependent
Immunocytochemistry (ICC)	Assay dependent
Immunohistochemistry (IHC) - frozen	1:10-1:50 (1-5 µg/ml)
Immunohistochemistry (IHC) - paraffin	1:10-1:500 (0.1-5 µg/ml; microwave treatment recommended)
Western Blot (WB)	1:50-1:500 (0.1-1 µg/ml)


Background

Ks 19.2 represents an excellent marker to discriminate glandular epithelial carcinoma from those of different origin. No reaction with hepatocellular carcinoma! Polypeptide Reacting: Mr 40,000 polypeptide (keratin K19; formerly also designated cytokeratin 19) of human glandular epithelia. The epitope has been localized on aa. 352-368 (VRADSERQNQEYQRLMD) of the alpha-helical fragment.


Tumors specifically detected: all tested adenocarcinoma; cholangio carcinoma of liver; renal cell carcinoma; transitional cell carcinoma of the bladder; ovary carcinoma; squamous cell carcinoma of cervix, bronchus and lung (intermediate type); mesothelioma; carcinoid tumor of bronchus; breast carcinoma; thymoma.

Reactivity on cultured cell lines: MCF-7.


Product images



Human head and neck squamous-cell carcinoma (HNSCC) (courtesy of J.Heß, University)



Human head and neck squamous-cell carcinoma (HNSCC) (courtesy of J.Heß, University)



Western blot analysis of human MCF-7 cell lysate with anti-Keratin K19 antibody. Western blot analysis was performed on 10 μg or 5 μg of MCF-7 lysate. Cells were lysed in PBS by homogenization. The PVDF membrane was blocked with 5% dry milk in PBST for 1 h at RT. The primary antibody anti-Keratin K19 mouse monoclonal, Ks19.2 (Z105.6; Cat. No. 690029) was diluted in blocking buffer (antibody concentration 0.1 $\mu\text{g}/\text{ml}$) and incubated for 1 h at RT. The secondary antibody goat anti-mouse IgG polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 0.2 $\mu\text{g}/\text{ml}$) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.

References

Publication	Species	Application
Van Der Gaast ^{â€™}, A. et al. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. Br. J. Cancer 69, 525â€“528 (1994).	human	ELISA
Bosch, F. X. et al. Extensive changes in cytokeratin expression patterns in pathologically affected human gingiva. Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol. 58, 59â€“77 (1989).	human	IHC (frozen)
Qiu, R. et al. Transplantation of fetal liver tissue coated by ultra-purified alginate gel over liver improves hepatic function in the cirrhosis rat model. Sci.Rep. 10, 8231 (2020)	rat	IHC (frozen)
MÃ¶bus, V. J. et al. Establishment of new ovarian and colon carcinoma cell lines: differentiation is only possible by cytokeratin analysis. Br. J. Cancer 69, 422â€“428 (1994).	human	ICC-IF
Bader, B. L. & Franke, W. W. Cell type-specific and efficient synthesis of human cytokeratin 19 in transgenic mice. Differentiation. 45, 109â€“118 (1990).	human	IHC (frozen)